What's new? Log in Free sign up

Disc Medicine (IRON)

Company Profile

Company profile

Ticker

IRON

Exchange

Website

geminitherapeutics.com

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology (except Nanobiotechnology)

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

FS Development Corp., Gemini Therapeutics, Inc. /DE

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Disc Medicine Opco, Inc. • Disc Medicine Securities Corp. • Gemini Therapeutics Sub, Inc.. ...

IRS number

851613057

IRON stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$95.00

Low target

$73.00

High target

$118.00

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Disc Medicine Announces Proposed Public Offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

Notice of effectiveness

Prospectus supplement for primary offering

Prospectus update (post-effective amendment)

Entry into a Material Definitive Agreement

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart IRON financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	192.87 mm	192.87 mm	192.87 mm	192.87 mm	192.87 mm	192.87 mm
Cash burn (monthly)	29.34 mm	14.82 mm	10.95 mm	10.41 mm	5.79 mm	7.01 mm
Cash used (since last report)	124.97 mm	63.10 mm	46.64 mm	44.32 mm	24.65 mm	29.87 mm
Cash remaining	67.91 mm	129.78 mm	146.23 mm	148.55 mm	168.23 mm	163.01 mm
Runway (months of cash)	2.3	8.8	13.4	14.3	29.1	23.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

IRON institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	140	129	+8.5%
Opened positions	25	31	-19.4%
Closed positions	14	40	-65.0%
Increased positions	60	54	+11.1%
Reduced positions	26	30	-13.3%

13F shares	Current	Prev Q	Change
Total value	1.28 tn	1.19 tn	+7.9%
Total shares	40.12 mm	39.84 mm	+0.7%
Total puts	7.30 k	11.40 k	-36.0%
Total calls	7.40 k	33.10 k	-77.6%
Total put/call ratio	1.0	0.3	+186.4%

Largest owners	Shares	Value	Change
Ai Dmi	3.76 mm	$168.79 mm	0.0%
Access Industries Management	3.35 mm	$165.35 mm	0.0%
Atlas Venture Life Science Advisors	2.51 mm	$123.31 bn	0.0%
BlackRock	1.85 mm	$90.97 bn	NEW
Wellington Management	1.84 mm	$90.43 bn	+4.8%
Bain Capital Life Sciences Investors	1.80 mm	$88.24 bn	0.0%
Bain Capital Life Sciences Opportunities III	1.80 mm	$81.89 mm	+34.8%
Orbimed Advisors	1.79 mm	$87.74 bn	0.0%
Frazier Life Sciences Management	1.75 mm	$86.23 bn	0.0%
Paradigm Biocapital Advisors	1.50 mm	$73.60 bn	-44.6%

Largest transactions	Shares	Bought/sold	Change
BlackRock	1.85 mm	+1.85 mm	NEW
BLK BlackRock	0.00	-1.44 mm	EXIT
Paradigm Biocapital Advisors	1.50 mm	-1.21 mm	-44.6%
Bain Capital Life Sciences Opportunities III	1.80 mm	+463.19 k	+34.8%
JHG Janus Henderson	749.83 k	+303.95 k	+68.2%
Polar Capital	0.00	-244.93 k	EXIT
STT State Street	827.91 k	+235.12 k	+39.7%
Perceptive Advisors	387.02 k	-166.42 k	-30.1%
Armistice Capital	160.00 k	+160.00 k	NEW
First Turn Management	0.00	-138.91 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IRON insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 Feb 25	Rahul Khara	Common Stock	Sell	Dispose S	No	Yes	56.0079	1,813	101.54 k	14,035
3 Feb 25	Rahul Khara	Common Stock	Sell	Dispose S	No	Yes	55.395	5,687	315.03 k	15,848
3 Feb 25	Rahul Khara	Common Stock	Option exercise	Acquire M	No	Yes	14.69	7,500	110.18 k	21,535
3 Feb 25	Rahul Khara	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	14.69	7,500	110.18 k	64,804
2 Jan 25	Rahul Khara	Common Stock	Sell	Dispose S	No	Yes	64.1347	2,100	134.68 k	14,035
2 Jan 25	Rahul Khara	Common Stock	Sell	Dispose S	No	Yes	62.9539	1,400	88.14 k	16,135
2 Jan 25	Rahul Khara	Common Stock	Sell	Dispose S	No	Yes	61.9599	4,000	247.84 k	17,535
2 Jan 25	Rahul Khara	Common Stock	Option exercise	Acquire M	No	Yes	14.69	7,500	110.18 k	21,535
2 Jan 25	Rahul Khara	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	14.69	7,500	110.18 k	72,304
31 Dec 24	John D Quisel	Common Stock	Option exercise	Acquire M	No	No	1.01	10,000	10.10 k	82,065

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Stifel Maintains Buy on Disc Medicine, Raises Price Target to $94

Stifel analyst Benjamin Burnett maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $90 to $94.

Reported Earlier, Disc Medicine Prices $225.5M Upsized Offering Of 3,918,182 Common Shares At $55 Each And 181,818 Warrants At $54.9999 Each

Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, to support the potential commercialization of bitopertin for

Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $73

Scotiabank analyst Greg Harrison maintains Disc Medicine (NASDAQ:IRON) with a Sector Outperform and raises the price target from $70 to $73.

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Disc Medicine Announces Proposed $200M Public Offering Of Common Stock and Pre-Funded Warrants

Press releases

From Benzinga Pro

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data,

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.